藥明康德(02359.HK)午後曾升10% 昨斥10億人幣回購A股
藥明康德(02359.HK)下午升幅擴大,最高見49.9元,一度升9.79%。現報49.65元,升9.24%,成交1,146.72萬股,涉資5.39億元。
該公司公布,昨日(5日)首次回購2,027.54萬股A股,每股作價介乎46.5-51.72元人民幣,資金總額10億人民幣,即回購方案資金總額上限。至今,股份回購已實施完畢。
藥明生物(02269.HK)最高見18.26元。現報18.12元,升4.74%,成交7,220.92萬股,涉資12.56億元。
藥明合聯(02268.HK)最高見17.66元。現報17.5元,升5.04%,成交429.89萬股,涉資7,130.1萬元。(cy/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.